Fixed price, unfixed volume: the company is locked into a rate while the amount it can sell against it is climbing
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了一种情况:公司业务中重要部分的“价格/费率/费用”已经固定或合同约定,而“数量”正在上升或即将上升,从而公司业绩随数量增长而增长,而非依赖价格谈判。 在记录中,管理层讨论了: - 试剂收入增长,年化每台仪器的试剂消耗(pull-through)从2022年的低3万美元区间增加到2023年第二季度的中3万美元区间。 - 他们提到“annualized second quarter reagent pull-through has now increased to the mid-$30,000 range for both the PhenoCycler and HT”,并预期未来几年试剂收入年增长在这个范围。 - 他们强调“driving increased reagent pull-through”和“increased instrument pull-through”。 - 他们提到新推出的试剂面板(如PhenoCode signature panels)和2.0升级将提高系统吞吐量,从而增加试剂使用量。 这里的关键是:试剂的价格(每单位试剂的费用)是否已经固定?管理层没有明确说试剂价格是合同约定的,但通常试剂销售是按目录价格或合同价格,但这里没有明确提及价格固定。他们主要谈论的是“pull-through”即每台仪器的试剂消耗量,这是数量指标。他们预期随着安装基数增加和新产品推出,试剂消耗量会上升。 然而,问题要求的是“价格/费率/费用”已经固定,而“数量”正在上升。在生命科学工具行业,试剂通常按目录价销售,但价格可能因客户或合同而异。管理层没有明确说价格是固定的,而是强调数量增长。此外,他们提到“annualized reagent pull-through”是每台仪器的年化试剂收入,这隐含了价格和数量的结合,但并没有明确说价格是固定的。 另外,他们提到“reagent revenue growth to be in this range for the next several years”,这更多是预测,而不是说价格固定。 因此,我认为没有明确描述“价格已固定”的情况。他们主要关注的是提高系统利用率以增加试剂消耗,但价格本身可能仍是变量。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
ABR · Q4 2016 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing the Agency Business servicing portfolio at $13.6 billion with a fixed 48 basis point weighted average servicing fee that is already contracted and recurring. They explicitly note the portfolio is growing through recent originations, including $700 million closed in December, which will drive higher servicing income in Q 1. Management states they expect the portfolio to generate over $65 million annually and references growth from 2015 levels, indicating the reported Q4 results reflect a lower average volume during the quarter while the settled economics now scale with the increasing volume arriving in Q1.
FIX · Q1 2017 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing a situation where pricing is stable and contracts (backlog) lock in rates, while volume is rising through backlog growth and upcoming organic work. The Q1 results reflect lower seasonal volume, with the backlog supporting higher throughput ahead. This fits the criteria of settled rates on meaningful contracted business with 13% backlog increase driving volume step-up.
CHE · Q3 2022 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES Management describes Medicare reimbursement rates as already fixed by regulation (CMS), with the volume side now rising through a first significant expansion of clinical staff and patient capacity since the pandemic, plus strengthening admissions and weekly ADC growth in the second half. The reported quarter reflects lower volume (ADC down 4.